Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyDavid G. Pfister, Susan Darlow, Sharon Spencer et al.|Journal of the National Comprehensive Cancer Network|2020Cited by 1.4k
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018A. Dimitrios Colevas, Susan Darlow, Sue S. Yom et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 632
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017David J. Adelstein, Susan Darlow, Maura L. Gillison et al.|Journal of the National Comprehensive Cancer Network|2017Cited by 378
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Stuart J. Wong et al.|European Journal of Cancer|2018Cited by 267
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, Nabil F. Saba et al.|JAMA Oncology|2018Cited by 111